

BIONTECH

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

Oncology

Drug Class	Platform	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights/Collaborator
mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	Advanced melanoma (Adjuvant & Metastatic)					Global
		BNT112	Prostate cancer					Global
		BNT113	HPV16+ head and neck cancer ¹					Global
		BNT114	Triple negative breast cancer ³					Global
		BNT115	Ovarian cancer ¹					Global
		BNT116	NSCLC					Global
	iNeST (patient specific cancer antigen therapy)	RO7198457 (BNT122 ³)	1L melanoma with CPI ²					Genentech (global 50:50 profit/loss share)
			Multiple solid tumors					
	Intratumoral Immunotherapy	SAR441000 (BNT131)	Solid tumors (<i>IL-12sc</i> , <i>IL-15sushi</i> , <i>GM-CSF</i> , <i>IFNα</i>)					Sanofi (global profit/loss share)
	RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple solid tumors					Global
		BNT142	Multiple solid tumors (<i>CD3+CLDN6</i>)					Global
	RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple solid tumors (<i>Optimized IL-2</i>)					Global
		BNT152, BNT153	Multiple solid tumors (<i>IL-7, IL-2</i>)					Global
	Cell Therapies	CAR-T Cells	BNT211	Multiple solid tumors (<i>CLDN6</i>)				Global
			BNT212	Pancreatic, other cancers (<i>CLDN18.2</i>)				Global
Neoantigen-based T cell therapy		BNT221 (NEO-PTC-01)	Multiple solid tumors				Global	
TCRs		To be selected	All tumors				Global	
Antibodies	Next-Gen CP ⁴ Immunomodulators	GEN1046 (BNT311)	Multiple solid tumors (<i>PD-L1x4-1BB</i>)				Genmab (global 50:50 profit/loss share)	
		GEN1042 (BNT312)	Multiple solid tumors (<i>CD40x4-1BB</i>)					
SMIM ⁵	Targeted Cancer Antibodies	BNT321 (MVT-5873)	Pancreatic cancer (<i>sLea</i>)				Global	
		Toll-Like Receptor Binding	BNT411	Solid tumors (<i>TLR7</i>)				Global

Other

Drug Class	Platform	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights/Collaborator	
mRNA	Infectious Disease Immunotherapies	BNT161	Influenza					Pfizer	
		BNT162	COVID-19					Fosun Pharma (China), Pfizer (Global, except China)	
		To be selected	Up to 10 indications					Penn ⁶	
		To be selected	HIV and tuberculosis					Bill & Melinda Gates Foundation	
		Rare Disease PRT ⁷	BNT171	Not disclosed					Genevant (global 50:50 profit/loss share)
			To be selected	4 more rare disease indications					

¹ BNT113 and BNT115 are currently being studied in investigator-initiated phase 1 trials

² Checkpoint Inhibitor

³ BNT114 is investigated in arm 1 (N=12) and arm 3 (N=15) of the TNBC-MERIT trial (total patients in study: N=42); BNT122 (iNeST) is also being investigated in arm 2 (N=15) of the 3 arm TNBC-MERIT trial, with BNT114 as an optional treatment

⁴ Checkpoint

⁵ Small Molecule Immunomodulators

⁶ We are eligible to receive worldwide licenses

⁷ Protein Replacement Therapy